H2020Индивидуална стипендия2015–2017

VesSenDrugDeliv · A versatile platform for the design of targeting drug delivery vesicles

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2015-07-01 → 2017-06-30
Финансиране от ЕС
195 455 €
Участници
1
Схема
MSCA-IF-EF-ST

Линиите свързват координатора с партньорите.

Накратко на български

Молекулярна платформа за създаване на наночастици помага за прецизното доставяне на лекарства директно до туморните клетки. Това е важно, за да се увеличи ефективността на терапията и да се намалят вредите върху здравите тъкани.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

A versatile platform for the design of targeting drug delivery vesicles

Even though great progress has been made in the understanding of fundamental cancer biology and cancer therapy, the translation from fundamental research to advances in clinic is yet to be better addressed. One of the major issues is to selectively deliver the therapeutic cargos to the desired target so that collateral damage can be minimized. The project “A Versatile Platform for the Design of Targeting Drug Delivery Vesicles”, abbreviated “VesSenDrugDeliv”, was to discover a versatile molecular platform that can be used to co-assemble with various functional moieties in aqueous solution to prepare efficient targeting drug delivery nanoparticles. By doing so, we aimed to use this type of nanoparticles to increase the targeting selectivity and enhance the therapeutic efficacy toward targeted tumour cells. Significant transfer of knowledge was involved during my stay at Imperial College London sponsored by this MSCA-IF fellowship. This includes the training acquired in using the-state-of-the-art facility such as transmission electron microscope (TEM), scanning electron microscope (SEM) and circular dichroism (CD). There were great opportunities of building-up worldwide collaboration with top scientists from UK, France and Australia. I was also able to develop invaluable supervision and management skills when mentoring master and Ph.D. students with different background. Moreover, the multinational culture and multidisciplinary environment at the Stevens Group at has fully supported the multidisciplinary “VesSenDrugDeliv” project.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

In the project of Marie Sklodowska-Curie Fellowship, I will design a versatile molecular platform that is used to construct multifunctional amphiphiles, which co-assemble with amphiphilic gold nanoparticles (AuNPs) to form monodisperse and stable targeting drug delivery vesicles. By incorporating multiple targeting ligands and multiple hydrophilic and hydrophobic drugs, I aim to discover efficient vesicle formulation with increased targeting selectivity and potent cytotoxicity to tumor cells. The route of the targeted drug delivery will be followed spontaneously via transiting surface plasmon resonance of AuNPs, and the impact of the targeted drug delivery on the targeted tumor cells will be monitored in real time by live cell Raman micro-spectroscopy. Furthermore, any targeting ligand, hydrophilic and hydrophobic drug can be easily tuned for a variety of different targeted tumour cells.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз